Search | Clinical Trials Finder

Conditions: Lung Transplant; Complications
Interventions: Etanercept Injection [Enbrel]; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rheumatoid Arthritis
Interventions: GDC-0853; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 11
States / cities: Glendale, Arizona • Covina, California • El Cajon, California + 7 more

Conditions: Spondylitis, Ankylosing
Interventions: Tocilizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 19
States / cities: Huntington Beach, California • Aventura, Florida • Miami, Florida + 16 more

Conditions: Rheumatoid Arthritis
Interventions: no intervention; Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 34
States / cities: Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 29 more

Conditions: Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD)
Interventions: Infliximab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 10 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Pancreatitis (AP), Gallstone Pancreatitis, Alcoholic Pancreatitis, Trauma Acute Pancreatitis, Hypertriglyceridemia Acute Pancreatitis, Idiopathic (Unknown) Acute Pancreatitis, Medication Induced Acute Pancreatitis, Cancer Acute Pancreatitis, Miscellaneous (i.e. Acute on Chronic Pancreatitis)
Interventions: Pentoxifylline, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, DMARDs; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Baricitinib, cDMARD; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 32
States / cities: Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more

Conditions: Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
Interventions: Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 67
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more

Conditions: Arthritis Rheumatoid
Interventions: Tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 7,807 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis
Interventions: Vedolizumab; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Crohn's Disease
Interventions: Placebo (IP), Ustekinumab 1mg/kg (IP), Ustekinumab 3 mg/kg (IP), Ustekinumab 6 mg/kg (IP), Placebo IV - Responder - Placebo SC (MP), Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP), Ustekinumab IV - Responder - Placebo SC (MP), Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP), Ustekinumab IV - Nonresponder - Placebo SC (MP), Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP); Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 88
States / cities: Mobile, Alabama • Scottsdale, Arizona • La Jolla, California + 85 more

Conditions: Rheumatoid Arthritis, Cardiovascular Disease
Interventions: Certolizumab; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 35 Years to 90 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: sarilumab SAR153191 (REGN88), tocilizumab, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide, subcutaneous placebo, intravenous placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more

Conditions: Rheumatoid Arthritis
Interventions: Teriparatide, calcium citrate, Vitamin D, TNF antagonist; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts • Worcester, Massachusetts

Conditions: Recurrent Aphthous Stomatitis
Interventions: Apremilast 30mg; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma
Interventions: TILT-123, Avelumab; Biological · Drug
Lead sponsor: TILT Biotherapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis
Interventions: Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 9
States / cities: Lakewood, Colorado • Maitland, Florida • Naples, Florida + 6 more

Conditions: Axial Spondyloarthritis, Ankylosing Spondylitis
Interventions: Not listed
Lead sponsor: Eyal Kedar; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Potsdam, New York

Conditions: Axial Spondyloarthritis (AxSpA)
Interventions: Secukinumab (IL-17i ), Upadacitinib (JAKi); Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ulcerative Colitis
Interventions: Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 4
States / cities: Orlando, Florida • Topeka, Kansas • Mentor, Ohio

Conditions: Rheumatoid Arthritis
Interventions: Baricitinib, TNF Inhibitor; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 119
States / cities: Chandler, Arizona • Mesa, Arizona • Paradise Valley, Arizona + 104 more

Conditions: Spondylitis, Ankylosing
Interventions: tocilizumab, Placebo; Biological · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 15
States / cities: Huntington Beach, California • Aventura, Florida • Orlando, Florida + 12 more

Search by objective public record fields.

RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant

A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350

A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab

Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease

Pentoxifylline Treatment in Acute Pancreatitis (AP)

Rheumatoid Arthritis Memory B Cells and Abatacept

A Moderate to Severe Rheumatoid Arthritis Study

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

CD40L Antagonism in Rheumatoid Arthritis (RA)

Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.

Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

Lipids, Inflammation, and CV Risk in RA

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

Apremilast for RAS

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis?

A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

A Study of Baricitinib in Participants With Rheumatoid Arthritis

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs